FDA updates ibuprofen compounding guidance
The Food and Drug Administration yesterday revised its recent guidance for outsourcing facilities compounding certain ibuprofen oral suspension products to help hospitals and health systems meet demand for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms. The revision addresses outsourcing facilities providing certain ibuprofen oral suspension products to dispense to patients for home use after receiving a patient-specific prescription from a health care provider.
Related News Articles
Headline
The market for pharmacy benefit manager services is highly concentrated, with commercial insurers often sharing ownership in the PBM, according to an analysis…
Headline
The Federal Trade Commission will launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers to…
Headline
As recommended by the AHA, the Food and Drug Administration today proposed revising 2016 draft guidance to allow hospital and health system…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
Regulators should prohibit health insurers from preventing hospitals and physicians in their networks from directly acquiring and storing drugs used in patient…